Wednesday, Nov. 10, 1999: In an effort to avoid a
threatened veto of a bill that would prohibit speculating in Internet
addresses or "Domain Names", (a practice known as
"cybersquatting"), leaders in Congress have inserted the
language of the bill into a satellite-television bill which has
already been passed in the House of Representatives and which is now
awaiting action in the Senate. This new action regarding the
'cybersquatting" bill is a major victory for Jack Valenti and
the Motion Picture Association of Amerrica, as well as for other
groups that have been trying to protect trademarks online. The bill
was passed in the House yesterday, November 9, by an overwhealming
408 to 8 vote.
The Clinton White House had threatened to
veto such proposed legislation, but it favors the satellite measure
as a way to help satellite=TV companies compete with cable operators.
This new measure would permit trademark
owners as well as politicians and athletes--groups who have
lately become the targets of attempts to "highjack" their
names or symbols--to take civil action against anyone who registers
celebrity names or trademarks as Internet addresses with hopes of
reselling them for a profit. Maximum damages available under this
bill would be US$100,000.00
Last year (1998) the Administration picked
the Internet Corporation for Assigned Names and Numbers, or Icann, to
be the nonprofit entity responsible for running the Internet's domain
Wednesday, Nov. 10,1999: In Washington, D. C.
today the U. S. Food and Drug Administration
gave approval to the JOHNSON & JOHNSON CORPORATION to put its
drug Remicade on the market as a treatment for rheumatoid arthritis.
Remicade had already been marketed by JOHNSON & JOHNSON as a
treatment for the digestive disorder called Crohn's disease. With the
new approval, Remicade would then be able to compete with the
drug Enbrel, which was sold by the IMMUNEX CORPORATION and its
parent, the AMERICAN HOME PRODUCTS CORPORATION.
JOHNSON & JOHNSON said
that the wholesale price for an average patient's first-year treatment
with Remicade would be around US$9,500.00. Enbrel's cost for the
same first-year's treatment was about 20% more, at US$11,400.00. The
cheaper price of Remicade was expected to help those patients who
were having trouble getting their insurance companies to cover the
higher cost of Enbrel, which was the only other drug in Remicade's class.